-continued

```
435
                             440
                                                 445
Gly Lys
<210> SEQ ID NO 229
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: HER3 binding site for 10D1-derived clones
<400> SEQUENCE: 229
Cys Phe Gly Pro Asn Pro Asn Gln Cys Cys His Asp Glu Cys Ala Gly
                                    10
Gly Cys
<210> SEQ ID NO 230
<211> LENGTH: 5
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: 10D1 binding site motif 1
<400> SEOUENCE: 230
Pro Asn Pro Asn Gln
<210> SEO ID NO 231
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: 10D1 binding site motif 2
<400> SEQUENCE: 231
Asp Glu Cys Ala Gly
```

- 1. An antigen-binding molecule, optionally isolated, which is capable of binding to HER3, wherein the antigen-binding molecule comprises:
 - (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - HC-CDR1 having the amino acid sequence of SEQ ID NO:43
 - HC-CDR2 having the amino acid sequence of SEQ ID NO:46
 - HC-CDR3 having the amino acid sequence of SEQ ID NO:51; and
 - (ii) a light chain variable (VL) region incorporating the following CDRs:
 - LC-CDR1 having the amino acid sequence of SEQ ID NO:91
 - LC-CDR2 having the amino acid sequence of SEQ ID NO:94
 - LC-CDR3 having the amino acid sequence of SEQ ID NO:99.
- 2. The antigen-binding molecule according to any one of claims 1 to 6, wherein the antigen-binding molecule comprises:

- (i) a heavy chain variable (VH) region incorporating the following CDRs:
 - HC-CDR1 having the amino acid sequence of SEQ ID NO:41
 - HC-CDR2 having the amino acid sequence of SEQ ID NO:45
 - HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and
- (ii) a light chain variable (VL) region incorporating the following CDRs:
 - LC-CDR1 having the amino acid sequence of SEQ ID NO:88
 - LC-CDR2 having the amino acid sequence of SEQ ID NO:92
 - LC-CDR3 having the amino acid sequence of SEQ ID NO:95.
- 3. The antigen-binding molecule according to claim 1 or claim 2, wherein the antigen-binding molecule comprises:
 - a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and
 - a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.